Browsing by Author "Sayaca N."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    The effect of COVID-19 on patients recieving omalizumab treatment; [L'effet du COVID-19 sur les patients recevant un traitement par omalizumab]
    (Elsevier Masson s.r.l., 2023) Sayaca N.; Cansız K.A.; Yıldırım E.; Öztürk B.; Kırmaz C.
    Background and aim: Although exposure during drug administration and susceptibility to coronavirus disease-19 (COVID-19) infection secondary to immunomodulatory effects constitute potential risks for patients with chronic spontaneous urticaria (CSU) or asthma on omalizumab (OMZ), there is a risk of loss of response following discontinuation of OMZ. There are few studies describing the clinical course of COVID-19 in patients receiving OMZ. Materials and methods: A total of 103 patients on OMZ were included in the study between February 2021 and January 2022. Results: Fourteen (13.6%) of the patients participating in the study had SARS-CoV-2 infection, of whom 3 (21.4%) required hospitalization and 11 (78.6%) were treated in an outpatient clinic. During the pandemic, 17 (16.5%) of the patients interrupted their OMZ treatment. Patients on OMZ for six months or less had a lower rate of interruption (2.5%) than those on OMZ for more than 6 months (25.4%). Patients interrupted treatment for the following reasons: 3 (17.6%) had COVID-19, 10 (58.9%) did not attend the hospital visit due to concern about contamination with SARS-CoV-2, and 4 (23.5%) thought that OMZ treatment would facilitate contamination with SARS-CoV-2. After interrupting OMZ, 3 (25%) female patients and 5 (100%) male patients presented no worsening of their symptoms. Three (13%) of the patients on OMZ for asthma and 11 (13.8%) of those on the drug for urticaria had COVID-19 infection. Patients presenting CSU and severe asthma are completely different, with different potential consequences of OMZ interruption. Nine (52.9%) patients had aggravated symptoms following interruption of OMZ treatment. Three of them described worsening of asthma symptoms and a need to increment their maintenance therapy due to asthma exacerbation after nearly three weeks of interruption, and 6 of them had hives and pruritus as urticaria exacerbation nearly four weeks after interruption of OMZ. The asthma patients did not stop their other treatments, including inhaled corticosteroids. Conclusion: Use of OMZ does not increase the risk of SARS-CoV-2 infection, COVID-19-related pneumonia, or COVID-19-related hospitalization. We advise patients not to interrupt OMZ treatment during the COVID-19 pandemic unless advised to do so by their doctors, and we recommend that they receive instruction concerning self-administration of OMZ to avoid visiting hospitals in the event of a pandemic. © 2023 Elsevier Masson SAS
  • No Thumbnail Available
    Item
    The percentage of hesitation and factors associated with acceptance or refusal for COVID-19 vaccine: Does training about vaccines by allergist affect personal decision?; [Hésitations et facteurs associés à l'acceptation ou au refus de la vaccination contre la COVID-19: l’éducation thérapeutique sur les vaccins affecte-t-elle la décision personnelle ?]
    (Elsevier Masson s.r.l., 2023) Sayaca N.; Aşık Cansız K.; Yıldırım E.; Öztürk B.; Kırmaz C.
    Background and aim: As the impact of coronavirus disease (COVID)-19 arises worldwide, the effect of vaccines is protecting its importance. The aim of this study was to investigate the vaccination perspectives of patients and learn how many patients were persuaded to get vaccinated with the effect of the education provided by allergists. Materials and methods: A cross-sectional study was carried out among 200 adult patients in the outpatient clinic between February 2021 and January 2022. Patients filled out the anti-vaccination scale form and a questionnaire form developed by allergists. The training about COVID-19 vaccines has been given to the patients who did not consider getting vaccinated. The patients were called by phone and questioned whether they have been vaccinated or not, after 22 weeks. Results: Out of 200 patients participants, 60.5% were considering getting vaccinated. Patients who did not consider getting vaccinated comprised 45.7% of women and 31% of men. While 52.4% of primary school graduates considered getting vaccinated, 75% of high school graduates and 60.8% of higher education graduates were considering getting vaccinated. Major reasons for rejecting vaccination were concerns about side effects and allergy. While the majority of women (47.2%) who did not want to get vaccinated were concerned about vaccine side effects, the majority of men (34.6%) did not want to get vaccinated because they did not trust the efficacy of the vaccine. Vaccination rates have been increased with the training we provided to our patients who did not consider getting the vaccine. 76 patients could be reached by phone and 81.6% of them were vaccinated, and 18.4% were not. Conclusion: The vaccination rates of allergy patients who did not consider getting vaccinated were increased with the information provided by allergists. So, the allergists should give more attention for giving information and increasing the vaccination rates of covid-19. © 2022 Elsevier Masson SAS
  • No Thumbnail Available
    Item
    Exercise-Induced Anaphylaxis
    (Springer International Publishing, 2023) Sayaca N.
    Anaphylaxis is an acute, systemic reaction with a potential risk of death. The annual incidence is between 50 and 112 per 100,000 and the prevalence varies between 0.3 and 5.1%. Many risk factors have been identified for anaphylaxis. Anaphylaxis is a sudden onset and life-threatening systemic hypersensitivity reaction due to mast cell and basophil-derived mediators. Common clinical symptoms of anaphylaxis are redness of the skin, pruritus, urticaria, angioedema, morbilliform rash, shortness of breath, chest tightness, deep coughing, wheezing/bronchospasm, itching, sneezing, congestion, discharge in the nose, chest pain, tachycardia, palpitations, bradycardia, dysrhythmia, hypotension, feeling faint, mental change, loss of sphincter control, shock, arrest, dizziness, throbbing headache, feeling of death, restlessness, and confusion. Anaphylaxis can be triggered by exercise or physical activity. Exercise-induced anaphylaxis (EIA) and food-dependent exercise-induced anaphylaxis (FDEIA) are defined in this context. Anaphylaxis can occur during exercise or appear soon after. If the occurrence of anaphylaxis is related to pre-exercise food intake (especially a food to which the patient is sensitive), the terminology of FDEIA is used. The frequency of attacks in both EIA and FDEIA is variable. Generally, attacks do not occur with every exercise. Although both types of anaphylaxis have been reported in all age groups, especially in the 4–74 age range, it is usually seen in adolescent and young adult patients. It is seen slightly more in men than women. It is usually sporadic, but familial cases have also been reported. FDEIA can be classified as specific FDEIA or non-specific FDEIA according to the identification of a culprit food allergen. Symptoms of both FDIEA and EIA can occur at any stage of the exercise, from ten minutes to four hours after food allergen ingestion. Most patients ingest the culprit allergen four to five hours before exercise and can exercise independently. With the cessation of exercise, the symptoms usually improve and may completely disappear in mild cases. In terms of follow-up and treatment, it is important to limit and control the physical activities that trigger the symptoms. Also, training about anaphylaxis action plans should be given to all patients and an adrenaline autoinjector should be prescribed. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.